|
|
Time |
Source |
|
Announcement
|
|
| 20 May 2022 |
8:15 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis |
| 15 May 2022 |
8:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy |
| 11 May 2022 |
7:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: New nirsevimab data analyses reinforce efficacy against RSV |
| 04 May 2022 |
11:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Foundation S: Sanofi’s new philanthropic spearhead |
| 03 May 2022 |
6:00 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Annual General Meeting of May 3, 2022 |
| 28 Apr 2022 |
6:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 |
| 26 Apr 2022 |
11:47 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence |
| 14 Apr 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine |
| 07 Apr 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation |
| 04 Apr 2022 |
11:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board |
| |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis |
| 01 Apr 2022 |
6:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022 |
| 31 Mar 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines |
| 30 Mar 2022 |
6:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Availability of the Q1 2022 Memorandum for modelling purposes |
| 29 Mar 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets |
| |
2:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver |
| 28 Mar 2022 |
8:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency |
| 26 Mar 2022 |
2:00 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis |
| 18 Mar 2022 |
11:48 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris |
| 16 Mar 2022 |
10:18 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates |
| 15 Mar 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma |
| 14 Mar 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer |
| 09 Mar 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment |
| 08 Mar 2022 |
1:25 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Sanofi recognized by S&P as one of the most sustainability-committed companies |
| 03 Mar 2022 |
7:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Nirsevimab significantly protected infants against RSV disease in Phase 3 trial |
| 26 Feb 2022 |
5:05 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis |
| |
5:00 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria |
| 23 Feb 2022 |
10:15 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine |
| 22 Feb 2022 |
5:32 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors |
| 18 Feb 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program |
| 10 Feb 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis |
| 09 Feb 2022 |
5:00 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Olipudase alfa shown to provide sustained improvement across multiple clinical manifestations of ASMD |
| 04 Feb 2022 |
10:00 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease |
| |
6:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D |
| 03 Feb 2022 |
4:00 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity |
| 31 Jan 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation |
| 19 Jan 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis |
| 07 Jan 2022 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines |
| 04 Jan 2022 |
6:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Availability of the Q4 2021 Memorandum for modelling purposes |
| 15 Dec 2021 |
6:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation |
| 14 Dec 2021 |
2:00 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions |
| 13 Dec 2021 |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session |
| 08 Dec 2021 |
10:30 pm |
GNW
|
|
|
Sanofi - Aventis Groupe |
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma |
| 01 Dec 2021 |
6:30 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates |
| |
6:00 am |
GNW
|
|
|
Sanofi - Aventis Groupe |
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy |
| 05 Jun 2009 |
9:30 am |
PRN
|
|
|
Sanofi Aventis Groupe |
Reminder: Sanofi Aventis - Live Webcast: Breaki... |
| 11 Feb 2009 |
8:45 am |
PRN
|
|
|
Sanofi Aventis Groupe |
Laurence Debroux Appointed Chief Strategic Offi... |
| |
8:44 am |
PRN
|
|
|
Sanofi Aventis Groupe |
Jean-Pierre Lehner Appointed Chief Medical Officer |
| |
8:32 am |
PRN
|
|
|
Sanofi Aventis Groupe |
Elias Zerhouni, Scientific Advisor to the Chief... |